Recipharm

GenIbet Biopharmaceuticals, S.A. is a biopharmaceutical contract manufacturing company located in Oeiras, Portugal, specializing in the production of non-sterile biological active pharmaceutical ingredients for clinical trials. Founded in 2006, the company provides a range of services, including cGMP manufacturing, cell line development, process optimization, and scale-up for various expression systems. GenIbet also offers cGMP cell banking, viral clearance, assay development, and quality control assurance. With in-house capabilities for fill and finish processes, GenIbet enables clients to transition from laboratory research to clinical applications within a single facility. The company draws on the expertise of its main shareholder, iBET (Instituto de Biologia Experimental e Tecnológica), in molecular biology, virology, and cell culture to enhance its service offerings.

Consort Medical plc is a prominent developer and manufacturer of pharmaceuticals and drug delivery devices, operating globally in Europe, the United States, and the UK. The company functions through two main segments, Bespak and Aesica, offering a range of medical devices designed for inhaled, injectable, nasal, and ocular drug delivery, alongside point of care diagnostics. Additionally, Consort Medical specializes in the development, formulation, and manufacture of active pharmaceutical ingredients and finished dose drugs. Established in 1946 and based in Hemel Hempstead, the organization serves major pharmaceutical companies, providing comprehensive solutions that streamline the drug development process. This integrated approach not only enhances the efficiency of bringing drugs to market but also positions Consort Medical at the forefront of innovation in the pharmaceutical sector. As of April 2020, Consort Medical operates as a subsidiary of Recipharm Holdings Limited.

Sanofi - business is inhalation contract manufacturing business.

Kemwell’s pharmaceutical businesses

Cirrus Pharmaceuticals, founded in 1997 and located in Research Triangle Park, North Carolina, specializes in product development and analytical testing services. Registered as a cGMP Analytical Testing Facility with the U.S. Food & Drug Administration, Cirrus offers a range of research and development services, including physical and chemical characterization, formulation development, stability testing, and technical transfer for various dosage forms such as inhaled, nasal, oral, parenteral, topical, and transdermal products. The company emphasizes customer satisfaction through its scientific expertise and commitment to delivering quality services on time and within budget. By collaborating with clients worldwide, Cirrus aims to meet project goals effectively while providing exceptional value.

Kemwell provides customized process/ product development and manufacturing solutions to pharmaceutical and biopharmaceutical organizations.

MITIM S.r.l. is a pharmaceutical company based in Brescia, Italy, founded in 1972. It specializes in the development and manufacture of a variety of pharmaceutical products, including beta-lactam antibiotics, injectable sterile solutions, oral solids and liquids, and semi-solids such as gels and creams. The company also provides additional services, including the development of new formulations, validation of analytic and microbiological methods, stability studies compliant with ICH guidelines, and preparation of technical documentation in CTD format. Over the years, MITIM has continuously upgraded its production plant, initially established in 1982, to enhance manufacturing capabilities and meet rising quality standards. As of February 2016, MITIM S.r.l. operates as a subsidiary of Recipharm Italia S.p.A.

Nitin Lifesciences Limited is an Indian pharmaceutical company that specializes in the manufacturing of injectable drug products. Founded in 1994 and based in Karnal, India, it operates three WHO-GMP certified plants, including one in an excise-free zone in Paonta Sahib, Himachal Pradesh. The company produces a diverse range of products such as liquid ampoules, liquid vials, dry powders (both beta-lactam and non-beta-lactam), eye and ear drops, and lyophilized vials. Nitin Lifesciences offers over 200 formulations across various therapeutic areas, including antibiotics, analgesics, antiarthritics, antidiabetics, and anti-inflammatory medications, among others. Additionally, it provides contract manufacturing services to major Indian pharmaceutical companies, enhancing their production capacities. The company serves clients both domestically and internationally, and also supplies medicines for relief efforts by non-profit organizations.

OnTarget Chemistry is specialized in medicinal chemistry offering synthesis and analytical services.

Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently markets three previously Unapproved Marketed Drugs ("UMDs") in the United States, Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection), and Akovaz™ (ephedrine sulfate injection). The Company also develops products utilizing its proprietary drug delivery platforms, Micropump® (oral sustained release microparticles platform), along with its tangent technologies, LiquiTime® (a Micropump-derivative platform for liquid oral products) and Trigger Lock™ (a Micropump-derivative platform for abuse-resistant opioids). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology, particularly suited to the development of subcutaneously administered formulations. Current applications of Flamel's drug delivery products include sodium oxybate (Micropump®), extended-release of liquid medicines such as ibuprofen and guaifenesin (LiquiTime®, through a license arrangement with Elan Pharma International Limited for the U.S. Over-the-Counter market) and a current study of the delivery of exenatide utilizing the Medusa™ technology.

It might be simplistically stated that Lusomedicamenta is specialised in the manufacture of pharmaceutical products: solids, liquids and semi-solids. It might the be added the the company is focused on new products carrying out the management of the entire process under a key-in-hand system from product creation the the registration dossier. It would also be no exaggeration to declare that, and without ever deviating on the highest of quality standard, Lusomedicamenta produces over 150 formulas and cover 700 formats, exporting its products to over 45 countries worldwide. Each and every on of these statements, remais correct but still fails to define us. We are defined by our staff. Competent, highly qualified people, motivaded by innovative and future oriented projects and more than able to manage scope for expansion through competitive cost, swift creative processes and a pragmatic, flexible, innovative and creative vision. These are, unquestionably, the core competences ans assets that ensure the sastisfaction and confidence of our clients wich have enabled Lusomedicamenta to establish its position as a leading benchmark for the pharmaceutical sector.

The Corvette Group Pharmaceutical Services S.p.A. is a parent company that provides high-value services to the pharmaceutical industry through its subsidiaries. It is controlled by LBO Italia Investimenti S.p.A., a private equity firm focused on long-term industrial development and committed to maintaining high ethical and professional standards. The group's subsidiaries include Biologici Italia Laboratories, which specializes in the development and production of sterile injectable products, Liosintex, which offers bulk lyophilization for beta-lactam antibiotics, and Edmond Pharma, which focuses on the production and development of active pharmaceutical ingredients and final products. Corvette Group not only offers financial support to its subsidiaries but also enhances their operational capabilities through a professional management structure.

Cobra Biomanufacturing operates as a contract manufacturer of biopharmaceuticals.

AstraZeneca Biotech Laboratory engages in research of proteins produced by disease genes. The company is based in Södertälje, Sweden. As of January 1, 2009, AstraZeneca Biotech Laboratory operates as a subsidiary of Recipharm AB.

Arranta Bio LLC is a contract development and manufacturing organization specializing in the development and production of live biopharmaceutical products, particularly those targeting human microbiome-related diseases. Founded in 2019 and headquartered in Watertown, Massachusetts, the company offers a comprehensive range of services, including media formulation, cell banking, fermentation, lyophilization, and analytical services, all conducted under current Good Manufacturing Practices (cGMP). Arranta Bio operates a process development and cGMP manufacturing facility in Gainesville, Florida, where it focuses on bacterial fermentation, isolation, drying, and encapsulation processes for live biotherapeutic products. The company aims to support innovators in the healthcare sector in bringing effective treatments to market through its advanced manufacturing capabilities.

Vibalogics GmbH is a contract development and manufacturing organization based in Cuxhaven, Germany, that specializes in providing comprehensive services for the biopharmaceutical industry, particularly in the fields of oncolytic viral therapies, gene therapies, and vaccines. Established in 2002 and formerly known as Bioprotect Research GmbH, the company offers a range of services that include process development, cell and virus banking, drug production, fill and finish, as well as quality control and stability testing. Vibalogics collaborates with pharmaceutical companies, biotechnology firms, and academic institutions across Europe, the United States, and the Asia-Pacific region, focusing on supporting the advancement of complex live biological products. Since 2019, it has operated as a subsidiary of Ampersand Management LLC.